Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?
AD Amin, TL Peters, L Li… - Molecular …, 2017 - molecularcasestudies.cshlp.org
Gene-expression profiling and next-generation sequencing have defined diffuse large B-cell
lymphoma (DLBCL), the most common lymphoma diagnosis, as a heterogeneous group of …
lymphoma (DLBCL), the most common lymphoma diagnosis, as a heterogeneous group of …
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients
M Pfreundschuh, N Murawski… - British journal of …, 2017 - Wiley Online Library
Male sex is associated with unfavourable pharmacokinetics and prognosis in elderly
patients with diffuse large B‐cell lymphoma (DLBCL). We investigated higher rituximab …
patients with diffuse large B‐cell lymphoma (DLBCL). We investigated higher rituximab …
[HTML][HTML] Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707
Y Maeda, H Nishimori, I Yoshida, Y Hiramatsu… - …, 2017 - ncbi.nlm.nih.gov
The standard CHOP therapy for peripheral T-cell lymphoma has resulted in unsatisfactory
outcomes and it is still not clear what is the optimal front-line therapy. We conducted a …
outcomes and it is still not clear what is the optimal front-line therapy. We conducted a …
Posterior reversible encephalopathy syndrome associated with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) …
AE Floeter, A Patel, M Tran, MC Chamberlain… - … Myeloma and Leukemia, 2017 - Elsevier
Introduction The purpose of our study was to identify the key risk factors for the development
of posterior reversible encephalopathy syndrome (PRES) after administration of the …
of posterior reversible encephalopathy syndrome (PRES) after administration of the …
Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation …
V Pejša, Ž Prka, M Lucijanić, Z Mitrović… - Croatian medical …, 2017 - hrcak.srce.hr
Aim To assess the benefit of rituximab with dose-adjusted etoposide, prednisone, vincristine,
cyclophosphamide, and doxorubicin (R-DA-EPOCH) regimen as a first-line treatment for …
cyclophosphamide, and doxorubicin (R-DA-EPOCH) regimen as a first-line treatment for …
[HTML][HTML] 剂量调整的EP（ D） OCH 方案联合利妥昔单抗治疗新诊断双表达淋巴瘤的疗效分析
刘薇， 李健， 黄文阳， 刘宏， 李增军， 吕瑞… - Chinese Journal of …, 2017 - ncbi.nlm.nih.gov
双打击淋巴瘤(DHL) 多起源于生发中心(GCB) B 细胞, 在2016 年更新的WHO
淋巴肿瘤分类中已将其定义为独立亚型, 命名为伴MYC 及BCL2 和/或BCL6 重排的高级别B …
淋巴肿瘤分类中已将其定义为独立亚型, 命名为伴MYC 及BCL2 和/或BCL6 重排的高级别B …
[HTML][HTML] Unusual presentation of plasmablastic lymphoma involving ovarian mature cystic teratoma: a case report
Background Plasmablastic lymphoma (PBL) is relatively new clinical entity described as a
distinct subtype of diffuse large B-cell lymphoma (DLBCL). It is characterized by its …
distinct subtype of diffuse large B-cell lymphoma (DLBCL). It is characterized by its …
DA‐EPOCH‐R for post‐transplant lymphoproliferative disorders
CB DeStefano, V Malkovska, H Rafei… - European Journal of …, 2017 - Wiley Online Library
Background Post‐transplant lymphoproliferative disorders (PTLD) are a potentially fatal
group of neoplasms arising in an immunodeficient environment. Although the cornerstone of …
group of neoplasms arising in an immunodeficient environment. Although the cornerstone of …
Clinical and cost comparison evaluation of inpatient versus outpatient administration of EPOCH-containing regimens in non-Hodgkin lymphoma
SS Evans, AS Gandhi, AB Clemmons… - Journal of Pharmacy …, 2017 - journals.sagepub.com
Background: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH)-
containing regimens are frequently utilized in non-Hodgkin's lymphoma, however, the …
containing regimens are frequently utilized in non-Hodgkin's lymphoma, however, the …
Factors and costs associated with delay in treatment initiation and prolonged length of stay with inpatient EPOCH chemotherapy in patients with hematologic …
Reducing delays related to inpatient chemotherapy may reduce healthcare costs. Using a
national database, we identified patients with lymphoma/leukemia with≥ 1 etoposide …
national database, we identified patients with lymphoma/leukemia with≥ 1 etoposide …